Suraksha Diagnostic Limited — Investor Meet, 30-12-2024: Analysts/Institutional Investor Meet/Con. Call Updates

1. Financial Performance: Suraksha Diagnostic reported total income of INR 680.7 million for Q2 FY25, representing a year-on-year growth of 12.3%. For H1 FY25, total income rose 14.5% to INR 1,299.2 million. EBITDA for Q2 increased by 14.6%, reaching INR 245.1 million, while H1 EBITDA was up 24.9% at INR 462.3 million, leading to an EBITDA margin improvement of over 300 basis points year-over-year to 36.3%. The profit after tax (PAT) for Q2 surged 21.8% to INR 101.6 million, and for H1, PAT showed a robust growth of 45.3% at INR 178.2 million, with a PAT margin enhancement of 130 basis points to 15.2%.

2. Future Outlook and Growth Drivers: Management highlighted plans to consolidate its footprint in the core regions by enhancing operational capacities, launching more home collection services, and expanding the polyclinic model in Northern and Eastern India. They also seek opportunities for inorganic growth through acquisitions to further solidify their market position, especially due to the increasing shift towards organized diagnostic services.

3. Order Book and Operational Updates: The company aims to open 12-15 new centers annually to expand its reach, focusing on both B2C and B2B segments. The current mix is 94% B2C, contributing significantly to revenue.

4. Analyst Q&A Insights (Detailed):

- Revenue and Profitability: Analysts probed management regarding margin comparisons to competitors, who indicated that margins could improve by 300-400 basis points over the next 18-24 months as economies of scale kick in.

- Market Position and Competitive Landscape: Suraksha is positioned competitively with regional players comprising only 20% of its size, and management expressed confidence in capturing growth from a limited competition landscape.

- Operational Challenges or Risks: Management acknowledged challenges arising from slower than expected market recovery post-protests but expressed optimism for robust growth in H2 FY25.

- Capex and Capital Allocation: Plans for INR 70 crore annual capex focus on opening new centers, funded through internal accruals.

- Strategic Priorities and Long-Term Vision: There’s an emphasis on utilizing technology for operational efficiencies while enhancing customer outreach through polyclinics.

5. Market or Regulatory Updates: The Eastern Indian diagnostics market is expected to grow at a CAGR of 10.5% to 12.5%, supported by Suraksha's strategic positioning within an underserved market.

6. Strategic Focus Areas: Management is focused on evolving its integrated service model, expanding the scope of diagnostic services, and leveraging operational scale to enhance margins as patient volumes increase.

7. Investor Insight: Given Suraksha's strong financial performance, progressive growth strategies, and dominant market position in Eastern India, the outlook suggests potential for significant appreciation in value, aligning more with a ‘buy’ stance considering the solid fundamentals and growth trajectory.